Skip to main content
. 2020 May 28;20(2):1630–1636. doi: 10.3892/etm.2020.8809

Figure 3.

Figure 3

Liq treatment enhances the protein expression of ERβ and inhibits the activity of the PI3K/AKT/mTOR signaling pathway in TNBC cells. MDA-MB-231 cells were treated with DOX (1 ng/ml), Liq (40 µg/ml) or a combination of DOX (1 ng/ml) and Liq (40 µg/ml). Subsequently, the protein expression levels of ERβ, p-AKT, AKT, p-mTOR and mTOR were (A) determined by western blotting and (B) quantified. ERβ expression levels were increased in MDA-MB-231 cells treated with Liq (40 µg/ml) or the combined treatment, whereas the ratio of p-AKT/AKT and p-mTOR/mTOR was decreased, compared with the control group. *P<0.05 vs. the negative control group. #P<0.05 vs. the DOX-treated group. Liq, liquiritigenin; ERβ, estrogen receptor β; DOX, doxorubicin; p, phosphorylated; Ctrl, control.